GSK-3β, a pivotal kinase in Alzheimer disease

Alzheimer disease (AD) is the most common form of age-related dementia. The etiology of AD is considered to be multifactorial as only a negligible percentage of cases have a familial or genetic origin. Glycogen synthase kinase-3 (GSK-3) is regarded as a critical molecular link between the two histopathological hallmarks of the disease, namely senile plaques and neurofibrillary tangles. In this review, we summarize current data regarding the involvement of this kinase in several aspects of AD development and progression, as well as key observations highlighting GSK-3 as one of the most relevant targets for AD treatment.

• Publication year

  2014

• Venue

  Frontiers in Molecular Neuroscience

• Publication date

  2014-05-21

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.3389/fnmol.2014.00046PMID 24904272PMCID 4033045
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• β-amyloid impairs the regulation of N-methyl-D-aspartate receptors by glycogen synthase kinase 3.

  2014cited by this paper
• Glycogen synthase kinase-3 inhibitors: Rescuers of cognitive impairments.

  2014cited by this paper
• Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease

  2014cited by this paper
• Kinase-kinase interaction and modulation of tau phosphorylation.

  2013cited by this paper
• GSK-3β overexpression causes reversible alterations on postsynaptic densities and dendritic morphology of hippocampal granule neurons in vivo

  2013influential reference
• Inhibition of GSK3β-mediated BACE1 expression reduces Alzheimer-associated phenotypes.

  2013cited by this paper
• Dual effects of increased glycogen synthase kinase-3β activity on adult neurogenesis.

  2013cited by this paper
• Neuroinflammatory phenotype in early Alzheimer's disease.

  2013cited by this paper
• Inhibition of Glycogen Synthase Kinase-3 Ameliorates β-Amyloid Pathology and Restores Lysosomal Acidification and Mammalian Target of Rapamycin Activity in the Alzheimer Disease Mouse Model

  2012cited by this paper
• Roles of glycogen synthase kinase 3 in Alzheimer's disease.

  2012cited by this paper
• Lithium Treatment of APPSwDI/NOS22/2 Mice Leads to Reduced Hyperphosphorylated Tau, Increased Amyloid Deposition and Altered Inflammatory Phenotype

  2012cited by this paper
• Tau Protein and Adult Hippocampal Neurogenesis

  2012cited by this paper
• Does Lithium Prevent Alzheimer’s Disease?

  2012cited by this paper
• Treatment of Alzheimer's Disease with the GSK-3 Inhibitor Tideglusib: A Pilot Study

  2012cited by this paper
• Proteolytic processing of Alzheimer’s β‐amyloid precursor protein

  2012cited by this paper
• A pivotal role of GSK-3 in synaptic plasticity

  2012cited by this paper
• Tau and tauopathies.

  2012cited by this paper
• P1‐071: Intensity of dementia through latent variable modelling (I‐DeLV) in the AIBL cohort

  2012cited by this paper
• Exploring the binding sites of glycogen synthase kinase 3. Identification and characterization of allosteric modulation cavities.

  2011cited by this paper
• GSK3β Is Involved in the Relief of Mitochondria Pausing in a Tau-Dependent Manner

  2011cited by this paper
• Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial

  2011cited by this paper
• Cholinergic and neuroprotective drugs for the treatment of Alzheimer and neuronal vascular diseases. II. Synthesis, biological assessment, and molecular modelling of new tacrine analogues from highly substituted 2-aminopyridine-3-carbonitriles.

  2011cited by this paper
• Glycogen Synthase Kinase-3 in the Etiology and Treatment of Mood Disorders

  2011cited by this paper
• Glycogen Synthase Kinase-3

  2011cited by this paper
• Alzheimer's disease.

  2011cited by this paper
• Different Susceptibility to Neurodegeneration of Dorsal and Ventral Hippocampal Dentate Gyrus: A Study with Transgenic Mice Overexpressing GSK3β

  2011cited by this paper
• Glycogen synthase kinase-3β2 has lower phosphorylation activity to tau than glycogen synthase kinase-3β1.

  2011cited by this paper
• Glycogen Synthase Kinase 3 Inhibitors in the Next Horizon for Alzheimer's Disease Treatment

  2011cited by this paper
• Tau Protein Is Required for Amyloid β-Induced Impairment of Hippocampal Long-Term Potentiation

  2011cited by this paper
• GSK-3 Mouse Models to Study Neuronal Apoptosis and Neurodegeneration

  2011cited by this paper
• A kinesin signaling complex mediates the ability of GSK-3β to affect mood-associated behaviors

  2010cited by this paper
• Activation of Wnt signaling by lithium and rosiglitazone reduced spatial memory impairment and neurodegeneration in brains of an APPswe/PSEN1ΔE9 mouse model of Alzheimer's disease

  2010influential reference
• Lithium Improves Hippocampal Neurogenesis, Neuropathology and Cognitive Functions in APP Mutant Mice

  2010cited by this paper
• Regulation of AMPA Receptor Trafficking and Function by Glycogen Synthase Kinase 3*

  2010cited by this paper
• Altered synaptic plasticity in the mossy fibre pathway of transgenic mice expressing mutant amyloid precursor protein

  2010cited by this paper
• Proteolytic processing of tau.

  2010cited by this paper
• Murine Features of Neurogenesis in the Human Hippocampus across the Lifespan from 0 to 100 Years

  2010cited by this paper
• The B‐Cell Antigen Receptor

  2010cited by this paper
• Tau-knockout mice show reduced GSK3-induced hippocampal degeneration and learning deficits.

  2010cited by this paper
• Indirubin-3'-monoxime rescues spatial memory deficits and attenuates beta-amyloid-associated neuropathology in a mouse model of Alzheimer's disease.

  2010cited by this paper
• Does lithium protect against dementia?

  2010cited by this paper
• Sevoflurane impairs memory consolidation in rats, possibly through inhibiting phosphorylation of glycogen synthase kinase-3β in the hippocampus.

  2010cited by this paper
• MAP1B Regulates Axonal Development by Modulating Rho-GTPase Rac1 Activity

  2010cited by this paper
• Involvement of the p75NTR signaling pathway in persistent synaptic suppression coupled with synapse elimination following repeated long‐term depression induction

  2010cited by this paper
• MicroRNAs contribute to LTP in the hippocampus in vivo (Commentary on Wibrand et al.)

  2010influential reference
• Evidence that glycogen synthase kinase‐3 isoforms have distinct substrate preference in the brain

  2010cited by this paper
• GSK3β overexpression induces neuronal death and a depletion of the neurogenic niches in the dentate gyrus

  2010cited by this paper
• Alzheimer's disease-like pathological features in transgenic mice expressing the APP intracellular domain

  2009cited by this paper
• Increase of BDNF Serum Concentration in Lithium Treated Patients with Early Alzheimer's Disease

  2009cited by this paper
• The Functional Role of Glycogen Synthase Kinase—3 in Cell

  2009cited by this paper
• Lithium treatment in Alzheimer’s disease does not promote cognitive enhancement, but may exert long-term neuroprotective effects

  2009cited by this paper
• Calpain‐mediated truncation of GSK‐3 in post‐mortem brain samples

  2009cited by this paper
• A novel GSK-3beta inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo.

  2009influential reference
• Coexistences of insulin signaling-related proteins and choline acetyltransferase in neurons.

  2009cited by this paper
• GSK3beta, a centre-staged kinase in neuropsychiatric disorders, modulates long term memory by inhibitory phosphorylation at serine-9.

  2009cited by this paper
• Dendritic spine dynamics.

  2009cited by this paper
• Synaptic degeneration in Alzheimer’s disease

  2009cited by this paper
• Synapse elimination accompanies functional plasticity in hippocampal neurons

  2008cited by this paper
• Why is the amyloid beta peptide of Alzheimer's disease neurotoxic?

  2008cited by this paper
• Biochemistry of Tau in Alzheimer’s disease and related neurological disorders

  2008cited by this paper
• A feasibility and tolerability study of lithium in Alzheimer's disease

  2008cited by this paper
• Tau Aggregates: Toxic, Inert, or Protective Species?

  2008cited by this paper
• 2008 Alzheimer's disease facts and figures

  2008cited by this paper
• Amyloid-β Binds to the Extracellular Cysteine-rich Domain of Frizzled and Inhibits Wnt/β-Catenin Signaling*

  2008cited by this paper
• GSK-3β Is Required for Memory Reconsolidation in Adult Brain

  2008cited by this paper
• Amyloid activates GSK-3beta to aggravate neuronal tauopathy in bigenic mice.

  2008cited by this paper
• Amyloid-beta-induced neurotoxicity is reduced by inhibition of glycogen synthase kinase-3.

  2008cited by this paper
• Inhibition of glycogen synthase kinase 3 beta attenuates neurocognitive dysfunction resulting from cranial irradiation.

  2008cited by this paper
• LTP inhibits LTD in the hippocampus via regulation of GSK3beta.

  2007influential reference
• Increased level of active GSK‐3β in Alzheimer’s disease and accumulation in argyrophilic grains and in neurones at different stages of neurofibrillary degeneration

  2007cited by this paper
• Soluble Aβ Inhibits Specific Signal Transduction Cascades Common to the Insulin Receptor Pathway*

  2007cited by this paper
• GSK3β Activity Modifies the Localization and Function of Presenilin 1*

  2007cited by this paper
• Lithium reduces tau phosphorylation but not A beta or working memory deficits in a transgenic model with both plaques and tangles.

  2007cited by this paper
• Glycogen synthase kinase‐3 inhibition is integral to long‐term potentiation

  2007cited by this paper
• Earliest Stages of Tau Conformational Changes are Related to the Appearance of a Sequence of Specific Phospho-Dependent Tau Epitopes in Alzheimer's Disease

  2007cited by this paper
• Young and excitable: new neurons in memory networks

  2007cited by this paper
• Role of Glycogen Synthase Kinase-3 in Cell Fate and Epithelial-Mesenchymal Transitions

  2007cited by this paper
• N-terminal Cleavage of GSK-3 by Calpain

  2007cited by this paper
• Reducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model

  2007cited by this paper
• Lithium and risk for Alzheimer's disease in elderly patients with bipolar disorder

  2007cited by this paper
• Transgenic animal models of neurodegenerative diseases and their application to treatment development.

  2007influential reference
• Tau and tauopathies.

  2007cited by this paper
• Neuroprotective Effects of Regulators of the Glycogen Synthase Kinase-3β Signaling Pathway in a Transgenic Model of Alzheimer's Disease Are Associated with Reduced Amyloid Precursor Protein Phosphorylation

  2007cited by this paper
• Glycogen Synthase Kinase-3 (GSK3): Inflammation, Diseases, and Therapeutics

  2007cited by this paper
• Novel Phosphorylation Sites in Tau from Alzheimer Brain Support a Role for Casein Kinase 1 in Disease Pathogenesis*

  2007cited by this paper
• Glycogen synthase kinase 3: A key regulator of cellular fate

  2007cited by this paper
• Neuronal apoptosis and reversible motor deficit in dominant‐negative GSK‐3 conditional transgenic mice

  2007cited by this paper
• Regulation of phosphorylation of tau by cyclin‐dependent kinase 5 and glycogen synthase kinase‐3 at substrate level

  2006cited by this paper
• Glycogen synthase kinase 3beta phosphorylates Alzheimer's disease-specific Ser396 of microtubule-associated protein tau by a sequential mechanism.

  2006cited by this paper
• Threonine 41 in β-Catenin Serves as a Key Phosphorylation Relay Residue in β-Catenin Degradation†

  2006cited by this paper
• Cyclin-dependent protein kinase 5 primes microtubule-associated protein tau site-specifically for glycogen synthase kinase 3β

  2006cited by this paper
• Cumulative Activation of Akt and Consequent Inhibition of Glycogen Synthase Kinase-3 by Brain-Derived Neurotrophic Factor and Insulin-Like Growth Factor-1 in Cultured Hippocampal Neurons

  2006cited by this paper
• The paradoxical pro- and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathways.

  2006cited by this paper
• The Roles of Cyclin-dependent Kinase 5 and Glycogen Synthase Kinase 3 in Tau Hyperphosphorylation*

  2006cited by this paper
• Role of MAP1B in axonal retrograde transport of mitochondria.

  2006cited by this paper
• Threonine 41 in beta-catenin serves as a key phosphorylation relay residue in beta-catenin degradation.

  2006cited by this paper
• Full Reversal of Alzheimer's Disease-Like Phenotype in a Mouse Model with Conditional Overexpression of Glycogen Synthase Kinase-3

  2006cited by this paper
• Distinct Morphological Stages of Dentate Granule Neuron Maturation in the Adult Mouse Hippocampus

  2006cited by this paper
• Alzheimer's disease

  2006cited by this paper
• The roles of cyclin‐dependent kinase 11 (CDK11) during mammalian development

  2006cited by this paper

• Therapeutic Potential of Nerve Growth Factor-Modified Hair Follicle Stem Cells Transplantation in a Rat Model of Alzheimer's Disease.

  2026cites this paper
• Pharmacophore-based approach for identifying compounds with myricetin-like pharmacophoric features as potential GSK3β inhibitors in Alzheimer’s disease

  2026cites this paper
• Design and synthesis of new phosphazine and triazole derivatives for treatment of Alzheimer's disease: modulating ROS/JNK and Wnt/β-catenin signaling pathways

  2026cites this paper
• Crocin Mitigates Glutamate Excitotoxicity and Tau Hyperphosphorylation by Modulating EAAT2 and Akt/Tau Pathway in a Scopolamine-induced Rat Model of Alzheimer's Disease.

  2026cites this paper
• Pubescenoside D Ameliorates Myocardial Ischemia–Reperfusion Injury via Preventing the Dissociation of HK2 and Promoting Mitophagy by Targeting GSK‐3β

  2025cites this paper
• 1-Deoxynojirimycin Combined with Theaflavins Targets PTGS2/MMP9 to Exert a Synergistic Hypoglycemic Effect

  2025cites this paper
• Natural products against tau hyperphosphorylation‐induced aggregates: Potential therapies for Alzheimer's disease

  2025cites this paper
• A multi enzyme study reviewing the role of target enzymes in Alzheimer’s disease and unveiling potential inhibitors with insights on their present and future assessment

  2025cites this paper
• Alzheimer’s Disease Pathogenic Mechanisms: Linking Redox Homeostasis and Mitochondria-Associated Metabolic Pathways Through Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2)

  2025cites this paper
• Fermented Soybean Pulp Alleviates Disease Progression of 5×FAD Model Mice

  2025cites this paper
• Advances in research on the pathogenesis and signaling pathways associated with postoperative delirium (Review)

  2025cites this paper
• Discovery of effective GSK-3β inhibitors as therapeutic potential against Alzheimer's disease: A computational drug design insight.

  2025cites this paper
• Microbial biomolecule-driven identification of next-gen GSK-3β inhibitors for brain disorders

  2025cites this paper
• Protective Effects of Apigenin in Neurodegeneration: An update on the Potential Mechanisms

  2025cites this paper
• Repurposing Saroglitazar for neurodegenerative disorders: insight into molecular signalling pathways and neuroprotective modulations

  2025cites this paper
• Neuroprotective Potential of Phytocompounds in the Treatment of Dementia: The State of Knowledge from the Scopolamine-Induced Animal Model of Alzheimer’s Disease

  2025cites this paper
• GSK-3β dysregulation in aging: Implications for tau pathology and Alzheimer's disease progression.

  2025cites this paper
• Therapeutic potential of 6BIO and DKK1-LRP6 inhibitor in Wnt/β-catenin pathway modulation for amyloid-β-induced Alzheimer's disease model

  2025cites this paper
• Dual Inhibitors Targeting G9a and GSK-3β: Translational Perspectives on Alzheimer’s Disease Treatment

  2025influential citation
• In silico decoding strategic pathways inhibition by coptisine for halting Alzheimer’s pathology: a mechanistic insight

  2025cites this paper
• Review of the evidence on the influence of Wi-Fi 2.4 GHz radiation on oxidative stress and its possible relationship with Alzheimer’s disease

  2025cites this paper
• From stress to Alzheimer's: A circuit-based framework for prefrontal cognitive dysfunction.

  2025cites this paper
• Phenolic compounds as anti-Alzheimer’s disease agents

  2025cites this paper
• Inhibition of glycolysis and stimulation of mitochondrial biogenesis lead to increased ROS levels and cell death in HNF-1ß positive clear cell carcinoma

  2025cites this paper
• The Unified Theory of Neurodegeneration Pathogenesis Based on Axon Deamidation

  2025cites this paper
• Lipopolysaccharides from Porphyromonas gingivalis indirectly induce neuronal GSK3β-dependent synaptic defects and cause cognitive decline in a low-amyloid-β-concentration environment in Alzheimer's disease

  2025cites this paper
• Massive changes in gene expression and their cause(s) can be a unifying principle in the pathobiology of Alzheimer's disease

  2025cites this paper
• Research on secondary metabolites of the oyster endophytic fungus Penicillium griseofulvum QDYM-3 and their anti-Alzheimer's disease activity.

  2025cites this paper
• Dietary supplements for prevention of Alzheimer’s disease: In vivo and in silico molecular docking studies

  2025cites this paper
• Harnessing the power of ginger leaf polysaccharide: A potential strategy to combat Aβ-induced toxicity through the Wnt/β-catenin pathway.

  2025cites this paper
• Targeting of PP2 A/GSK3β/PTEN Axis in Alzheimer Disease: The Mooting Evidence, Divine, and Devil

  2025cites this paper
• Tauopathy in AD: Therapeutic Potential of MARK-4.

  2025cites this paper
• TREM2 activation reduces white matter injury via PI3K/Akt/GSK‐3β signalling after intracerebral haemorrhage

  2025cites this paper
• Regulation of Apoptotic Pathways by MicroRNAs: A Therapeutic Strategy for Alzheimer’s Disease

  2025cites this paper
• Accumulation of GSK‐3β in Interneurons Impairs Adult Hippocampal Neurogenesis by Inhibiting GABAergic Transmission

  2025cites this paper
• Oligodendroglia in Ageing and Age-Dependent Neurodegenerative Diseases.

  2025cites this paper
• Unveiling the role of erinacines in the neuroprotective effects of Hericium erinaceus: a systematic review in preclinical models

  2025cites this paper
• Ambroxol confers neuroprotection against scopolamine-induced Alzheimer’s-like pathology by modulating oxidative stress, neuroinflammation, and cognitive deficits via Nrf-2/JNK/GSK-3β signaling pathways

  2025cites this paper
• Targeting GSK-3β to Modulate the Wnt Pathway: A Promising Neuroprotective Strategy for Alzheimer's Disease.

  2025cites this paper
• Computational identification of phytochemicals as glycogen synthase kinase 3 beta (GSK3β) inhibitors for therapeutic applications in chronic diseases

  2025cites this paper
• Genetic drivers of progression in Alzheimer’s disease are distinct from disease risk

  2025cites this paper
• NEUROPROTECTIVE EFFECTS OF DONEPEZIL AND FLUOXETINE VIA GSK-3 PATHWAY IN A TRANSGENIC DROSOPHILA MODEL OF ALZHEIMER'S DISEASE: NEUROPSYCHIATRIC AND BEHAVIOURAL ANALYSIS

  2025cites this paper
• In Silico Pharmacological and Pharmacokinetic Study of Marmeline From Bael Fruit for the Treatment of Alzheimer’s Disease

  2025cites this paper
• Exercise training enhances myokine release and reduces brain insulin resistance: insights into muscle-CNS metabolic cross-talk

  2025cites this paper
• Recent advancement in polysaccharides from Cornus officinalis Sieb. et Zucc.: Extractions, purifications, structural characteristics, bioactivities, and applications: A review.

  2025cites this paper
• Integrative machine learning and molecular simulation approaches identify GSK3β inhibitors for neurodegenerative disease therapy

  2025cites this paper
• An updated patent review of acetylcholinesterase inhibitors for the treatment of Alzheimer’s disease (2021–present)

  2025cites this paper
• Paeonol mitigates chronic stress-induced amygdalar neuronal damage through glycogen synthase kinase-3β/calcineurin axis regulation of synaptic plasticity.

  2025cites this paper
• Pharmacological modulation of the PI3K/AKT/GSK3β axis: a new frontier in Alzheimer’s disease treatment

  2025cites this paper
• Protein misfolding and neurodegeneration: Mechanisms, implications, and therapeutic strategies.

  2025cites this paper
• Glycogen synthase kinase-3 activation and dysregulation of amyloid transport receptors expression and shedding in HIV-induced Alzheimer’s disease-like pathology: modulatory effects of CCR5 antagonists

  2025cites this paper
• Mitochondria‐Associated Membranes: A Key Point of Neurodegenerative Diseases

  2025cites this paper
• Exome sequencing of a Portuguese cohort of early-onset Alzheimer’s disease implicates the X-linked lysosomal gene GLA

  2025cites this paper
• Murine Non-Transgenic Models of Alzheimer’s Disease Pathology: Focus on Risk Factors

  2025cites this paper
• The Neuroprotective Effect of Rooibos Herbal Tea Against Alzheimer's Disease: A Review

  2024cites this paper
• Terpenes as Potential Anti-Alzheimer’s Disease Agents

  2024cites this paper
• First in Class Dual Non-ATP-Competitive Glycogen Synthase Kinase 3β/Histone Deacetylase Inhibitors as a Potential Therapeutic to Treat Alzheimer's Disease.

  2024cites this paper
• Positive Effects of Argon Inhalation After Traumatic Brain Injury in Rats

  2024cites this paper
• Isoindolinedione-Benzamide Pyridinium Derivatives for Targeting Alzheimer’s Disease

  2024cites this paper
• Loss of calcium/calmodulin-dependent protein kinase kinase 2, transferrin, and transferrin receptor proteins in the temporal cortex of Alzheimer’s patients postmortem is associated with abnormal iron homeostasis: implications for patient survival

  2024cites this paper
• Amelioration of cisplatin-induced neurodegenerative changes in rats and restoration of mitochondrial biogenesis by 6-bromoindirubin-3'-oxime: The implication of the GSK-3β/PGC1-α axis.

  2024cites this paper
• Systemic Treatment with siRNA Targeting Gamma-Secretase Activating Protein Inhibits Amyloid-β Accumulation in Alzheimer’s Disease

  2024cites this paper
• Exosomal MicroRNAs in Alzheimer’s Disease: Unveiling Their Role and Pioneering Tools for Diagnosis and Treatment

  2024cites this paper
• Mitochondria-targeting by small molecules against Alzheimer's disease: A mechanistic perspective.

  2024cites this paper
• GSK-3 kinase a putative therapeutic target in trypanosomatid parasites

  2024cites this paper
• Therapeutic Potential Effect of Glycogen Synthase Kinase 3 Beta (GSK-3β) Inhibitors in Parkinson Disease: Exploring an Overlooked Avenue

  2024influential citation
• Navigating the GSK-3β inhibitors as versatile multi-target drug ligands in Alzheimer’s disease intervention – A comprehensive review

  2024cites this paper
• Potential Neuroprotective Role of Neurotrophin in Traumatic Brain Injury.

  2024cites this paper
• Dual-target inhibitors of cholinesterase and GSK-3β to modulate Alzheimer's disease.

  2024cites this paper
• Impact of GSK-3β and CK-1δ on Wnt signaling pathway in alzheimer disease: A dual target approach.

  2024cites this paper
• Wnt/β-catenin Signaling in Central Nervous System Regeneration.

  2024cites this paper
• Gastrodin ameliorates synaptic impairment, mitochondrial dysfunction and oxidative stress in N2a/APP cells.

  2024cites this paper
• Therapeutic mechanism of Convolvulus pluricaulis against Alzheimer's disease: Network pharmacology and molecular dynamics approach

  2024cites this paper
• Practical Three-Component Regioselective Synthesis of Drug-Like 3-Aryl(or heteroaryl)-5,6-dihydrobenzo[h]cinnolines as Potential Non-Covalent Multi-Targeting Inhibitors To Combat Neurodegenerative Diseases.

  2024cites this paper
• A new bithiophene inhibited amyloid-β accumulation and enhanced cognitive function in the hippocampus of aluminum-induced Alzheimer's disease in adult rats

  2024cites this paper
• Danggui Shaoyao San Alleviates Early Cognitive Impairment in Alzheimer's Disease Mice Through IRS1/GSK3β/Wnt3a‐β‐Catenin Pathway

  2024cites this paper
• Novel Insights into Famotidine as a GSK-3β Inhibitor: An explorative study in aluminium chloride-induced Alzheimer's Disease rat model.

  2024cites this paper
• Unveiling neuroprotective mechanisms of diosgenin and pterostilbene in diabetes-associated Alzheimer’s disease through multi-target molecular docking approach

  2024cites this paper
• Anti-oxidant activity of coenzyme Q10 against AlCl3/D-galactose in albino rat induced cognitive dysfunctions: Behavioral, biochemical, and BACE-1/GSK-3β alterations.

  2024cites this paper
• Chronic rapid eye movement sleep deprivation aggravates the pathogenesis of Alzheimer’s disease by decreasing brain O-GlcNAc cycling in mice

  2024cites this paper
• Influence of Exercise and Genistein to Mitigate the Deleterious Effects of High-Fat High-Sugar Diet on Alzheimer’s Disease-Related Markers in Male Mice

  2024cites this paper
• Brain Metabolism in Health and Neurodegeneration: The iInterplay Among Neurons and Astrocytes

  2024cites this paper
• Anti-oxidative stress and cognitive improvement of a semi-synthetic isoorientin-based GSK-3β inhibitor in rat pheochromocytoma cell PC12 and scopolamine-induced AD model mice via AKT/GSK-3β/Nrf2 pathway.

  2024cites this paper
• Rhei Undulati Rhizoma attenuates memory decline and reduces amyloid-β induced neuritic dystrophy in 5xFAD mouse

  2024cites this paper
• Molecular docking studies and molecular dynamic simulation analysis: To identify novel ATP-competitive inhibition of Glycogen synthase kinase-3β for Alzheimer’s disease

  2024cites this paper
• Decoding the molecular Symphony: Unravelling neurologically crucial GSK-3 inhibition through 2D QSAR modelling with MLR, PLS, and ANN approaches

  2024cites this paper
• Benzimidazole‐oxindole hybrids: A novel class of selective dual CDK2 and GSK‐3β inhibitors of potent anticancer activity

  2024cites this paper
• Evolving Significance of Kinase Inhibitors in the Management of Alzheimer's Disease.

  2024cites this paper
• Emerging role of Metformin in Alzheimer's disease: A translational view.

  2024cites this paper
• A New Frontier in Phytotherapy: Harnessing the Therapeutic Power of Medicinal Herb-derived miRNAs.

  2024cites this paper
• ERRα and ERRγ coordinate expression of genes associated with Alzheimer’s disease, inhibiting DKK1 to suppress tau phosphorylation

  2024cites this paper
• An interpretable deep learning framework identifies proteomic drivers of Alzheimer’s disease

  2024cites this paper
• Akt-activated GSK3β inhibitory peptide effectively blocks tau hyperphosphorylation

  2024cites this paper
• Exploring the Therapeutic Potential of Glycyrrhiza Compounds in Alzheimer's Disease: A Comprehensive Review.

  2024cites this paper
• The Goldilocks paradigm: comparing classical machine learning, large language models, and few-shot learning for drug discovery applications

  2024cites this paper
• Presenilin deficiency enhances tau phosphorylation and its secretion

  2024cites this paper
• Design of Multi-Target drugs of HDACs and other Anti-Alzheimer related Targets: Current strategies and future prospects in Alzheimer's diseases therapy.

  2024cites this paper
• Regulation of Glycogen Synthase Kinase-3β by Phosphorylation and O-β-Linked N-Acetylglucosaminylation: Implications on Tau Protein Phosphorylation.

  2024cites this paper
• Exploring the therapeutic potential of rosemary compounds against Alzheimer’s disease through GC-MS and molecular docking analysis

  2024cites this paper
• Therapeutic approaches in proteinopathies.

  2024cites this paper